Journal of Clinical Oncology Journal
Overview
Publication venue for
- Area deprivation index and breast cancer subtypes in young patients. 41. 2023
- Association of intensive chemotherapy with the rate of pathogenic driver mutation clearance in acute myeloid leukemia. 41. 2023
- De novo metastatic Her2+breast cancer in a diverse population of women under age 40. 41. 2023
- Differences in perceptions and use of remote patient monitoring technology in rural cancer programs. 41. 2023
- Early real-world (RW) experience with a multi-cancer early detection (MCED) test.. 41. 2023
- Evaluating the diagnostic performance of F-18-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. 41. 2023
- Gaps in care planning and delivery for patients with liver cancer: Baseline assessment for implementation of 4R Oncology model. 41. 2023
- Obesity and breast cancer in women under age 40.. 41. 2023
- Obesity and triple negative breast cancer diagnosis among premenopausal women.. 41. 2023
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. 41:2673-2681. 2023
- A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.. 41:361-361. 2023
- Factors influencing the initiation of adjuvant endocrine therapy in patients with Estrogen receptor-positive ductal carcinoma in situ: A single institution experience.. 40:E18569-E18569. 2022
- Implications of 18F-FDG PET/CT findings before autologous stem cell transplant in patients with multiple myeloma.. 40. 2022
- Molecular profiling of African American patients with pancreatic cancer.. 40:E16242-E16242. 2022
- Pathologic and clinical outcomes after neoadjuvant modified FOLFIRINOX and gemcitabine and NAB-paclitaxel for pancreatic cancer.. 40:E16236-E16236. 2022
- Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.. 40. 2022
- A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.. 39. 2021
- Survey results of patients with neuroendocrine cancer to find an overall high satisfaction with telemedicine and identify weaknesses of telemedicine unique to patients with rare cancers.. 39. 2021
- Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.. 39. 2021
Identity
International Standard Serial Number (ISSN)
- 0732-183X